FeesSafety
Pluang+

Pfizer beats Q3 revenue estimates, raises 2026 guidance, and shows strong margin growth.

Analyst Insights
18 Nov 2026, 08:15 WIB
Seeking Alpha
View Source
Bullish
Pfizer beats Q3 revenue estimates, raises 2026 guidance, and shows strong margin growth.

Pfizer reported Q3 revenue of $16.58 billion, exceeding estimates by $700 million, driven by a 32% growth in launched and acquired products and an improved gross margin of about 77%. The company raised its full-year 2026 revenue guidance to $62 billion–$64 billion and adjusted EPS guidance to $2.95–$3.05, with conservative expectations for Q4. Despite some caution over pricing pressures on Eliquis and market share losses for Prevnar, Pfizer remains attractively valued with a 5.95% dividend yield and a price-to-earnings ratio of 9.6 times the guidance midpoint.

As of Nov 18, 2026 13:11 WIB, Pfizer (PFE) shares trade at USD 28.35 on Pluang, down 1.77% for the day with a market cap of $164.50 billion. Despite the recent price dip, the stock maintains an attractive dividend yield of 5.96%, supporting its appeal to income-focused investors. The typical holding period on Pluang is 158 days, indicating moderate investor confidence in the stock's medium-term prospects.

More News (PFE)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App